source
- Alnylam to launch pivotal Huntington’s trial after early study shows strong huntingtin knockdownAlnylam Pharmaceuticals announced plans to move its Huntington’s disease RNAi therapy brezosiran into a pivotal, placebo‑controlled trial slated for 2027, pending regulatory alignment. The decisio…
- Tango’s pancreatic cancer combo shows striking promise at ESMO, building on Revolution Medicines’ earlier successTango presented new data on its pancreatic cancer combination at the opening of the ESMO conference, highlighting a striking level of activity that builds on earlier success reported by Revolution…STAT · 17d agoPositive readoutPositive